Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Coherus Bio
(NQ:
CHRS
)
2.120
-0.050 (-2.30%)
Official Closing Price
Updated: 4:15 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Coherus Bio
< Previous
1
2
3
Next >
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
February 13, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
February 03, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
January 09, 2023
Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
December 25, 2022
From
Junshi Biosciences
Via
GlobeNewswire
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
December 24, 2022
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
November 08, 2022
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
November 01, 2022
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical
October 12, 2022
From
Coherus BioSciences, Inc.; Shanghai Junshi Biosciences Co., Ltd
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.